Ocuphire Pharma, Inc. (OCUP) [Rocket]

Date Filed	Type	Description
05/28/2019	GN	Rexahn Announces Move to Nasdaq
05/13/2019	GN	Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results
04/19/2019	GN	Analysis: Positioning to Benefit within Nordic American Tankers, Safeguard Scientifics, Permian Basin Royalty Trust, Coda Octopus Group, Rexahn Pharmaceuticals, and Diversified Restaurant ?? Research Highlights Growth, Revenue, and Consolidated Results
04/16/2019	GN	Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
04/12/2019	GN	Rexahn Effects 1-for-12 Reverse Stock Split
04/10/2019	GN	Rexahn Announces Reverse Stock Split
03/27/2019	GN	Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting
03/08/2019	GN	Rexahn Pharmaceuticals Reports 2018 Financial Results
03/01/2019	GN	Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
02/06/2019	GN	Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium
02/04/2019	GN	Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types
01/24/2019	GN	Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
01/22/2019	GN	Rexahn Announces Proposed Public Offering of Common Stock and Warrants
01/22/2019	GN	Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
01/14/2019	GN	Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium
12/11/2018	GN	Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings